ANIK Anika Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ANIK

Price (delayed)

$27.27

Market cap

$402.43M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.54

Enterprise value

$350.97M

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Anika Therapeutics partners with clinicians to understand what they need ...

Highlights
The company's gross profit rose by 13% YoY
Anika Therapeutics's gross margin has increased by 8% YoY
The company's EPS has shrunk by 51% QoQ
The net income has declined by 50% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.anikatherapeutics.com
Peers: MDT SYK JNJ HALO

Key stats

What are the main financial stats of ANIK
Market
Shares outstanding
14.76M
Market cap
$402.43M
Enterprise value
$350.97M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.44
Price to sales (P/S)
2.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.23
Earnings
Revenue
$157.47M
EBIT
-$27.05M
EBITDA
-$10.64M
Free cash flow
-$4.89M
Per share
EPS
-$1.54
Free cash flow per share
-$0.33
Book value per share
$18.97
Revenue per share
$10.75
TBVPS
$17.67
Balance sheet
Total assets
$339.07M
Total liabilities
$61.49M
Debt
$28.28M
Equity
$277.59M
Working capital
$131.64M
Liquidity
Debt to equity
0.1
Current ratio
5.59
Quick ratio
3.85
Net debt/EBITDA
4.84
Margins
EBITDA margin
-6.8%
Gross margin
60.1%
Net margin
-14.1%
Operating margin
-18%
Efficiency
Return on assets
-6.4%
Return on equity
-7.9%
Return on invested capital
-15.1%
Return on capital employed
-8.7%
Return on sales
-17.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANIK stock price

How has the Anika Therapeutics stock price performed over time
Intraday
2.06%
1 week
-0.37%
1 month
5.57%
1 year
23.84%
YTD
-7.87%
QTD
-5.05%

Financial performance

How have Anika Therapeutics's revenue and profit performed over time
Revenue
$157.47M
Gross profit
$94.62M
Operating income
-$28.4M
Net income
-$22.28M
Gross margin
60.1%
Net margin
-14.1%
Anika Therapeutics's operating income has plunged by 54% YoY and by 46% from the previous quarter
The net income has declined by 50% since the previous quarter
Anika Therapeutics's net margin has decreased by 48% QoQ
Anika Therapeutics's operating margin has decreased by 46% YoY and by 45% from the previous quarter

Growth

What is Anika Therapeutics's growth rate over time

Valuation

What is Anika Therapeutics stock price valuation
P/E
N/A
P/B
1.44
P/S
2.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.23
The company's EPS has shrunk by 51% QoQ
ANIK's price to book (P/B) is 24% less than its 5-year quarterly average of 1.9 but 11% more than its last 4 quarters average of 1.3
ANIK's equity is down by 2.9% year-on-year and by 2.8% since the previous quarter
ANIK's P/S is 38% below its 5-year quarterly average of 4.1
The revenue has grown by 4.8% YoY

Efficiency

How efficient is Anika Therapeutics business performance
Anika Therapeutics's ROE has plunged by 52% from the previous quarter
The return on assets has declined by 49% since the previous quarter
The company's return on sales fell by 43% QoQ
The ROIC is down by 40% since the previous quarter

Dividends

What is ANIK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIK.

Financial health

How did Anika Therapeutics financials performed over time
Anika Therapeutics's quick ratio has decreased by 13% YoY and by 11% from the previous quarter
Anika Therapeutics's total liabilities has increased by 9% YoY but it has decreased by 3.3% from the previous quarter
Anika Therapeutics's debt is 90% lower than its equity
Anika Therapeutics's debt has surged by 50% YoY
The debt to equity is up by 43% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.